Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

NÎMES, France–(BUSINESS WIRE)–Regulatory News:

Advicenne (Paris:ADVIC), a specialty pharmaceutical company focused on
the development of pediatric-friendly therapeutics for the treatment of
orphan renal and neurological diseases, announced today that it has
received a No Objection Letter to extend its ARENA-2 pivotal Phase III
trial for the treatment of distal Renal Tubular Acidosis (dRTA) in
Canada from Health Canada’s Office of Clinical Trial.

After clearance obtained in September from the United States FDA,
this new milestone will allow Advicenne to accelerate the recruitment of
patients for our ARENA-2 pivotal Phase III trial for ADV7103 in dRTA and
enlarges the company’s perspective in North America,”
stated Dr.
Luc-André Granier, Chief Executive Officer of Advicenne.

About ARENA-2

ARENA-2 is a pivotal Phase III, prospective, multicenter, randomized,
double-blinded, placebo-controlled study expected to enroll
approximately 40 patients in the United States and now Canada. The
primary objective of the study is to evaluate the safety and efficacy of
ADV7103 versus placebo in preventing the development of metabolic
acidosis defined by serum bicarbonate level in pediatric (6 months to <
18 years of age) and adult (18 to 65 years of age) subjects with primary

About distal Renal Tubular Acidosis (dRTA)

dRTA is a disease that occurs when the kidneys do not properly remove
acids from blood into urine. As a result, acid overload generates an
unbalanced blood pH that triggers failure to thrive and rickets (a
condition that affects bone development in children), as well as a range
of additional clinical disorders such as a potassium deficiency
(hypokalemia) in blood serum, thus altering the function of several
organs and most prominently affecting the cardiovascular system. In
addition, a high concentration of calcium in blood and urine
(hypercalcemia and hypercalciuria, respectively) can lead to kidney
stones and calcinosis which may potentially cause renal impairment and
ultimately renal failure. Either genetic or acquired as a result of
autoimmune disease, dRTA is estimated to affect 30,000 patients in
Europe and 20,000 in the United States.

About Advicenne

Advicenne (Euronext: ADVIC) is a specialty pharmaceutical company
developing pediatric-friendly therapeutics for the treatment of orphan
renal and neurological diseases. The Company’s lead product is ADV7103
which has demonstrated positive results in a European pivotal Phase III
study in children and adults with distal Renal Tubular Acidosis (dRTA),
is also being developed for a second indication, Cystinuria, an
inherited renal tubulopathy.

Advicenne is planning to file ADV7103 for market authorization for dRTA
in Europe in the next coming months and anticipates its commercial
launch in 2020 in Europe. In North America, the United States FDA and
Health Canada gave clearance to commence a pivotal Phase III clinical
trial assessing ADV7103 in dRTA patients. Commercial launch in the
United States is anticipated in 2021.

Advicenne is listed on the regulated market of Euronext in Paris (ISIN:
FR0013296746; Euronext ticker: ADVIC). The Company, which was
established in 2007, is headquartered in Nîmes, France.


Forward-Looking Statement

This press release contains certain forward-looking statements relating
to the business of Advicenne, which shall not be considered per se as
historical facts. Such statements include estimates for future
performance and estimates regarding anticipated operating losses, future
revenues, capital requirements, needs for additional financing. In some
cases, you can identify forward-looking statements by words such as
“could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets,” or similar words. Although
the management of Advicenne believes that these forward-looking
statements are reasonably made, they are based largely on the current
expectations of Advicenne as of the date of this press release and are
subject to a number of known and unknown risks and uncertainties and
other factors that may cause actual results, performance or achievements
to be materially different from any future results, performance or
achievement expressed or implied by these forward-looking statements. In
particular, the expectations of Advicenne could be affected by, among
other things, uncertainties involved in the placing on the market and
commercialization of Advicenne products or any other risk and
uncertainties developed or identified in any public documents filed by
Advicenne with the AMF, included those listed in chapter 4 “Risk
factors” of its document de base filed with the French financial market
authority (the Autorité des marches financiers) on October 31, 2017
under number I.17-071. Notwithstanding the compliance with article 223-1
of the General Regulation of the AMF (the information disclosed must be
“accurate, precise and fairly presented”), Advicenne disclaims any
intention or obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or


Luc-André Granier, Paul Michalet,
Rachline, Sarah Delbaere,
(0)4 66 05 54 20
US Investor Relations
Communications Group, LLC
Paula Schwartz
Press Relations
Alize RP
Carmagnol & Tatiana Vieira
(0)1 44 54 36 66
Financial communication
Huynh & Alexia Faure
(0)1 44 71 94 94


I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.